Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Dx Firm Atlas Genetics Lands $4.1M in VC Funds

NEW YORK (GenomeWeb News) – Atlas Genetics has gained £2.1 million ($4.1 million) in venture capital from previous and new investors, which it will use to conduct clinical evaluations for a clinical diagnostic test for Group B Streptococcus in pregnant women.
Investors in this round of financing included South West Ventures Fund, GEIF, and private investors through the SWAIN business angel’s network. New investors included Finance South West Growth Fund and Braveheart Ventures.
Atlas, a spin-out from Bath University in the UK, is developing a point-of-care portable system to deliver molecular diagnostic results in 30 minutes. The firm is working on tests for meningitis, Chlamydia, Group B Streptococcus and for methicillin-resistant Staphylococcus aureus.